Hereditary Transthyretin Amyloidosis With Polyneuropthy

0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
Data CollectionN/A1 trial
Active Trials
NCT04850105Recruiting240Est. Mar 2036

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
United TherapeuticsData Collection

Clinical Trials (1)

Total enrollment: 240 patients across 1 trials

A Non-interventional Cohort Safety Study of Patients With hATTR-PN

Start: Sep 2021Est. completion: Mar 2036240 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 240 patients
1 companies competing in this space